Last reviewed · How we verify
IR Tacrolimus
At a glance
| Generic name | IR Tacrolimus |
|---|---|
| Sponsor | University of California, Davis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients (PHASE4)
- Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PHASE2)
- Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PHASE4)
- Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence
- Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients (PHASE4)
- Early Use of Long-acting Tacrolimus in Lung Transplant Recipients (EARLY_PHASE1)
- Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes (NA)
- Envarsus XR in Lung Transplant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IR Tacrolimus CI brief — competitive landscape report
- IR Tacrolimus updates RSS · CI watch RSS
- University of California, Davis portfolio CI